Guardian Bio

Guardian Bio is a preclinical-stage biotechnology company developing a novel class of cell therapies based on plasmacytoid dendritic cells (pDCs). The company's platform focuses on leveraging the unique ability of pDCs to orchestrate a comprehensive immune response against cancer by activating both innate and adaptive immune pathways. By utilizing a proprietary manufacturing process to generate high-purity pDCs from stem cells, Guardian Bio aims to overcome the limitations of traditional dendritic cell vaccines and current T-cell therapies. The company is primarily focused on treating solid tumors that are resistant to existing immunotherapies. Their approach represents a first-in-class modality designed to bridge the gap between innate and adaptive immunity.